Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Net Income (2023 - 2025)

Zenas BioPharma has reported Net Income over the past 3 years, most recently at $148.1 million for Q4 2025.

  • Quarterly results put Net Income at $148.1 million for Q4 2025, up 361.91% from a year ago — trailing twelve months through Dec 2025 was $10.8 million (up 106.69% YoY), and the annual figure for FY2025 was $10.8 million, up 106.68%.
  • Net Income for Q4 2025 was $148.1 million at Zenas BioPharma, up from -$51.5 million in the prior quarter.
  • Over the last five years, Net Income for ZBIO hit a ceiling of $148.1 million in Q4 2025 and a floor of -$56.5 million in Q4 2024.
  • Median Net Income over the past 3 years was -$35.8 million (2024), compared with a mean of -$13.9 million.
  • Biggest five-year swings in Net Income: tumbled 208.37% in 2024 and later surged 361.91% in 2025.
  • Zenas BioPharma's Net Income stood at -$24.8 million in 2023, then plummeted by 128.15% to -$56.5 million in 2024, then surged by 361.91% to $148.1 million in 2025.
  • The last three reported values for Net Income were $148.1 million (Q4 2025), -$51.5 million (Q3 2025), and -$52.2 million (Q2 2025) per Business Quant data.